We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

68 hedge funds and large institutions have $92.1M invested in ImmunityBio in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

33% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 15

19.55% more ownership

Funds ownership: 0% → 19.55% (+20%)

8% more funds holding

Funds holding: 63 → 68 (+5)

1% more call options, than puts

Call options by funds: $80K | Put options by funds: $79K

41% less capital invested

Capital invested by funds: $155M → $92.1M (-$62.8M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
68
Holders Change
+5
Holders Change %
+7.94%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
14
Increased
20
Reduced
15
Closed
8
Calls
$80K
Puts
$79K
Net Calls
+$1K
Net Calls Change
-$812K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$970K
2
BFA
BlackRock Fund Advisors
California
+$946K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$587K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$354K
5
Morgan Stanley
Morgan Stanley
New York
+$327K

Top Sellers

1
CC
Callan Capital
California
-$26.5M
2
Franklin Resources
Franklin Resources
California
-$6.21M
3
Bank of America
Bank of America
North Carolina
-$960K
4
ACA
Avoro Capital Advisors
New York
-$563K
5
VEA
Virtus ETF Advisers
New York
-$295K
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
51
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$33K -$3.66K -548 -9%
Zurich Cantonal Bank
52
Zurich Cantonal Bank
Switzerland
$31K – – –
TRCT
53
Tower Research Capital (TRC)
New York
$27K +$30.3K +4,540 +8,566%
Barclays
54
Barclays
United Kingdom
$18K -$3.96K -594 -16%
BG
55
BlackRock Group
United Kingdom
$18K – – –
Legal & General Group
56
Legal & General Group
United Kingdom
$18K +$21.5K +3,224 New
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$16K -$5.58K -837 -23%
UBS Group
58
UBS Group
Switzerland
$14K -$2.47K -370 -13%
BlackRock
59
BlackRock
New York
$14K – – –
ClearBridge Investments
60
ClearBridge Investments
New York
$11K – – –
MAM
61
Meeder Asset Management
Ohio
$10K +$11.4K +1,705 New
CG
62
Cutler Group
California
$6K – – –
NFG
63
Next Financial Group
Texas
$4K – – –
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$3.51K -$5.88K -881 -59%
PNC Financial Services Group
65
PNC Financial Services Group
Pennsylvania
$3K -$6.67K -1,000 -67%
IP
66
Intellectus Partners
California
$1K +$667 +100 New
CC
67
Callan Capital
California
– -$26.5M -3,406,405 Closed
ACA
68
Avoro Capital Advisors
New York
– -$563K -72,412 Closed
VEA
69
Virtus ETF Advisers
New York
– -$295K -37,895 Closed
HCM
70
Highbridge Capital Management
New York
– -$210K -27,002 Closed
UBS AM
71
UBS AM
Illinois
– -$138K -17,700 Closed
MF
72
Magnetar Financial
Illinois
– -$105K -13,475 Closed
AIM
73
Acrospire Investment Management
Illinois
– -$16K -2,100 Closed
TWA
74
TCI Wealth Advisors
Arizona
– -$1K -100 Closed
SFS
75
Sowell Financial Services
Arkansas
– +$67 +10 New
1 2
3

IBRX Hedge Fund Activity: Q4 2016 in Review

68 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2016, worth a combined $92.1M — down 41% from $155M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IBRX positions and 8 closed out — a net gain of 6 holders — while 20 added to existing stakes and 15 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $970K. The largest seller was Callan Capital, exiting entirely with an estimated $26.5M sold.

  • 68 institutional investors held ImmunityBio (IBRX) as of Q4 2016, up from 63 in Q3 2016.
  • Funds reported $92.1M of ImmunityBio stock for Q4 2016, down 41% quarter-over-quarter.
  • 14 funds opened new ImmunityBio positions in Q4 2016 and 8 closed out, a net change of +6 holders.
  • The largest ImmunityBio buyer in Q4 2016 was Millennium Management, an estimated $970K added.
  • The largest ImmunityBio seller in Q4 2016 was Callan Capital, an estimated $26.5M sold.

Based on aggregated 13F filings for Q4 2016.